GlassScriptPhysician profile
Mark R Olsen
NPI 1356382592
$2,764.94
in general payments reported to CMS, 2019-2025
42 companies · $569 in 2025
The $569 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $310 · 2021: $381 · 2022: $308 · 2023: $346 · 2024: $544 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.38 |
| Education | $201.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $425.76 | 2020-2025 | Enhertu |
| Pfizer INC. | $347.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $225.45 | 2019-2024 | Opdivo |
| Allergan, INC. | $166.27 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $166.08 | 2019-2025 | |
| Gilead Sciences, INC. | $160.44 | 2019-2023 | Trodelvy |
| Seagen INC. | $117.01 | 2020-2023 | Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $105.00 | 2022 | |
| Genzyme Corporation | $93.34 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $82.49 | 2020-2024 | Xpovio |
| Taiho Oncology, INC. | $73.88 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.67 | 2023-2025 | Vpriv, Fruzaqla |
| Merck Sharp & Dohme LLC | $54.34 | 2022-2025 | Keytruda |
| Eisai INC. | $49.48 | 2024-2025 | |
| Beone Medicines USA, INC. | $47.26 | 2025 | Brukinsa |
Show all 38 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.